Genpact price target raised to $44 from $38 at Baird

Baird analyst David Koning raised the firm’s price target on Genpact to $44 from $38 and keeps a Neutral rating on the shares. The firm views the risk/reward as mildly positive and are warming to the stock; they like the valuation and historical steadiness along with H2 guidance appearing conservative. Baird expects Q3 revenue and EPS above Street with 2024 guidance likely narrowed/raised to the top end of previous guidance.